Investigational drug · Phase 2
Allogeneic umbilical cord mesenchymal stem cells
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for COVID-19 Infection, Multiple Sclerosis, ST Elevation Myocardial Infarction.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
146
Any phase or sponsor naming "Allogeneic umbilical cord mesenchymal stem cells"
First trial start
2020
Aug 5, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Allogeneic umbilical cord mesenchymal stem cells", any sponsor or status.
Conditions studied
As listed on its trial records.
- COVID-19 Infection
- Multiple Sclerosis
- ST Elevation Myocardial Infarction
Approved drugs for the same conditions: Coronary artery disease and heart attack · Multiple sclerosis · COVID-19 · Cardiovascular and metabolic · Neurology · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Allogeneic umbilical cord mesenchymal stem cells" as an intervention, largest first.
- Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic ShockPivotal-lookingRecruiting
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT05969275 · 296 participants (planned) · Start Feb 14, 2024 · Primary completion Sep 30, 2026
Drug: Allogeneic umbilical cord-derived human mesenchymal stromal cells · For: Septic Shock; Sepsis; Pathologic Processes and 4 more
Sites: Ottawa, Canada · 2 sites in all
- Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver FailurePivotal-lookingStatus unknown
Third Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT01844063 · 210 participants (planned) · Start Jul 2013 · Primary completion Jan 2016
Drug: Conventional treatment · For: Liver Failure
Sites: Guangzhou, China
- A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingNot yet recruiting
Darwin Origin (Hubei) Biopharmaceutical Co., Ltd.Industry
NCT07833618 · 150 participants (planned) · Start Sep 1, 2026 · Primary completion Jan 1, 2028
Drug: ALT001 1.0 μg/kg; ALT001 2.0 μg/kg and 1 more · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Beijing, China
- hCT-MSC in Children With Autism Spectrum DisorderPivotal-lookingCompleted
Joanne Kurtzberg, MDAcademic, hospital or other
NCT04089579 · 137 participants · Start Oct 12, 2020 · Primary completion May 2, 2023
Drug: Cord Tissue Mesenchymal Stromal Cells · For: Autism; Autism Spectrum Disorder
Sites: Durham, North Carolina
- Efficacy of Allogeneic Umbilical Cord Derived Hematopoietic and Mesenchymal Stem Cells in Cerebral PalsyPivotal-lookingStatus unknown
Tehran University of Medical SciencesAcademic, hospital or other
NCT03795974 · 108 participants · Start Jul 23, 2017 · Primary completion Oct 2019
Drug: MNC; MSC · For: Cerebral Palsy, Spastic
Sites: Tehran, Iran · 4 sites in all
- Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage InjuryPivotal-lookingCompleted
Medipost Co Ltd.Industry
NCT01041001 · 104 participants · Start Feb 2009 · Primary completion Dec 2010
Drug: Cartistem · For: Cartilage Injury; Osteoarthritis
Sites: Incheon, South Korea; Seoul, South Korea · 8 sites in all
- Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of TalusPivotal-lookingCompleted
Hyundai Bioland Co., Ltd.Industry
NCT04310215 · 102 participants · Start Mar 3, 2020 · Primary completion Jun 13, 2022
Drug: CARTISTEM® · For: Chondral or Osteochondral Lesion of Talus
Sites: Seoul, South Korea; Daejeon, South Korea; Incheon, South Korea · 6 sites in all
- MSC Infusion for Anti-aging and Regenerative TherapyStatus unknown
Landmark Medical Centre Sdn BhdAcademic, hospital or other
NCT04174898 · 100 participants (planned) · Start Apr 15, 2020 · Primary completion Apr 14, 2021
Drug: human Mesenchymal Stem Cell (MSC) infusion therapy · For: Aging Well; Regenerative Medicine
Sites: Johor Bahru, Malaysia
- Adia Med of Winter Park LLC Autism Spectrum Disorder Research StudyPivotal-lookingRecruiting
Adia Med of Winter Park LLCAcademic, hospital or other
NCT07304440 · 100 participants (planned) · Start May 1, 2026 · Primary completion Jun 15, 2028
Drug: Umbilical Cord Blood-Derived Stem Cells and Exosomes; Glutathione · For: Autism Spectrum Disorder; Autism; ASD and 1 more
Sites: Winter Park, Florida; Green Bay, Wisconsin
- Adia Med of Winter Park LLC Lower Back Pain Research StudyPivotal-lookingRecruiting
Adia Med of Winter Park LLCAcademic, hospital or other
NCT07587047 · 100 participants (planned) · Start Jun 16, 2026 · Primary completion Jan 2028
Drug: Umbilical Cord Blood-Derived Stem Cells and Exosomes · For: Chronic Mechanical Lower Back Pain; Lower Back Pain; Chronic Lower Back Pain
Sites: Winter Park, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Multimodal Biological Augmentation with Umbilical Cord Mesenchymal Stem Cell Secretome, Recombinant Human Bone Morphogenetic Protein-2, and Allogeneic Umbilical Cord Mesenchymal Stem Cells in Neurofibromatosis Type 1-Confirmed Congenital Pseudarthrosis of the Distal Tibia and Fibula: A Case Report with Mechanistic Scoping Review.
Anggitadewi LGD, Sindrawati O, Irianto KA, et al. · J Orthop Case Rep 2026
- Validation of [89Zr]Zr-oxine labelling and PET/CT imaging for tracking mesenchymal stem cells in mice and patients with perianal fistula.
Wang Y, Mu H, Gao L, et al. · Stem Cell Res Ther 2026
- Regenerative fibroblasts derived from autologous skin tissue for the treatment of Sjögren's syndrome: a case report.
Ma ZX, Wu XF, Cao L, et al. · Front Immunol 2025
- Revolutionizing Endodontics: Innovative Approaches for Treating Mature Teeth With Closed Apices and Apical Lesions: A Report of Two Cases.
Brizuela C, Meza G, Khoury M · J Endod 2024
- Allogeneic Cellular Therapy in a Mature Tooth with Apical Periodontitis and Accidental Root Perforation: A Case Report.
Cordero CB, Santander GM, González DU, et al. · J Endod 2020
- Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study.
Wang D, Niu L, Feng X, et al. · Clin Exp Med 2017
Also in development for COVID-19 Infection
- ibuzatrelvirPF-07817883Phase 32 trials
Pfizer · COVID-19 SARS-CoV-2 Infection, COVID-19 Infection
- COH04S1GEO-CM04S1, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1Phase 22 trials
GeoVax, Inc. · COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.